REVIEW article
Front. Bioeng. Biotechnol.
Sec. Cell and Gene Therapy
SLC26A9 in Triple-Negative Breast Cancer Stem Cells: A Network Pharmacology and Molecular Modeling Study
Provisionally accepted
Mimi Shen
Zhiyuan Ma
Yanghui CaoLan WangGuoli FengZhengxing Zhou
Leilei LiBei JiShuhui LiuJiaqi QinQin Wang
Xuemei Liu*
Taolang Li*- Affiliated Hospital of Zunyi Medical University, Zunyi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its high heterogeneity and lack of effective targeted therapies. Cancer stem cells (CSCs) play a crucial role in TNBC recurrence, metastasis, and drug resistance. However, the interplay between ion transport, microenvironmental regulation, and classical stemness pathways remains underexplored in existing reviews. In this work, we systematically integrated multi-omics databases, network pharmacology, protein–protein interaction (PPI) analysis, functional pathway enrichment, and molecular modeling to highlight the "bridging" role of SLC26A9 and its interacting proteins in TNBC stem cell self-renewal, drug resistance, and microenvironmental regulation. Comprehensive molecular docking and 100-ns molecular dynamics (MD) simulations demonstrated that the small molecule S9-A13 exhibited high affinity and stable binding to both SLC26A9 and tumor protein p53 (TP53), with docking affinities of –7.737 and –8.447 kcal/mol and molecular mechanics/generalized Born surface area (MM/GBSA) binding free energies of –34.47 and –25.65 kcal/mol, respectively. These results suggest that S9-A13 may act on the SLC26A9–TP53 axis to enable multi-target regulation of TNBC cancer stem cells. We further discuss the translational implications of such interventions, including safety profile considerations, potential off-target effects, and delivery strategies.. In summary, this review provides a structured framework and testable hypotheses for developing SLC26A9-based multi-target precision therapies for TNBC CSCs, while emphasizing that these computational findings are hypothesis-generating and require rigorous experimental and clinical validation prior to translation.
Keywords: Triple-negative breast cancer, cancer stem cells, SLC26A9, systemspharmacology, Network Pharmacology, Molecular modeling, TP53, precision oncology
Received: 11 Sep 2025; Accepted: 04 Nov 2025.
Copyright: © 2025 Shen, Ma, Cao, Wang, Feng, Zhou, Li, Ji, Liu, Qin, Wang, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xuemei Liu, onlyoneliuxuemei@163.com
Taolang Li, 0078029@sina.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.